Matthew Harrison

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market.  Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the...

Moderna Inc (NASDAQ: MRNA), a messenger RNA therapeutics company, recently offered 26.28 million shares priced at $23 each in an IPO. The Analyst Morgan Stanley analyst Matthew Harrison initiated coverage of Moderna with an Overweight rating and $29 price target. The Thesis Moderna has...

DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) shares were losing more than half of their value in Thursday trading following an update on the company's lead pipeline candidate. What Happened DBV said Wednesday after the close it has voluntarily withdrawn its Biologic License Application,...

A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded program’s stumble.  The Analyst Analyst Matthew Harrison upgraded...

Biopharma Cytokinetics Inc. (NASDAQ: CYTK) announced a delay in drug studies during its earnings call Thursday, prompting a downgrade by Morgan Stanley.  The Analysts Morgan Stanley's Matthew Harrison downgraded Cytokinetics from Overweight to Equal-Weight and lowered...

Neon Therapeutics Inc (NASDAQ: NTGN) develops vaccine based on neoantigens — markers unique to each individual tumor — to improve tumor response in checkpoint inhibitors such as Merck & Co., Inc. (NYSE: MRK)'s Keytruda and Bristol-Myers Squibb Co (NYSE: BMY)...

Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The candidate also posted  positive results in a late-stage trial that...

Incyte Corporation (NASDAQ: INCY)'s pipeline is devoid of any major catalysts in 2018, according to Morgan Stanley.  The Analyst Analyst Matthew Harrison downgraded Incyte from Overweight to Equal-weight and maintained a $76 price target.  The Thesis Many of Incyte's...

Evelo Biosciences Inc (NASDAQ: EVLO), a clinical stage biotechnology company that focuses on mining the gut for therapetuics that can modulate the immune system, boasts "significant" platform potential, according to Morgan Stanley. The Analyst Morgan Stanley's Matthew Harrison...

Unity Biotechnology Inc (NASDAQ: UBX) has fallen 22 percent since its May 3 initial public offering. Nonetheless, three sell-side firms initiated price targets implying significant upside Tuesday. The Rating Morgan Stanley analysts Matthew Harrison and David Lebowitz initiated coverage on Unity...

Loxo Oncology Inc (NASDAQ: LOXO) holds an opportunity to differentiate itself among RET inhibitors while developing medicines for patients with genetically defined cancers, according to Morgan Stanley.  RET, or rearranged during transfection, is a certain type of mutation in protein that...

Multiple small- and mid-cap biotech stocks have benefited from a strong run, prompting Morgan Stanley to downgrade three companies in the group. The Analyst Morgan Stanley's Matthew Harrison downgraded the following: Sarepta Therapeutics Inc (NASDAQ: SRPT) from Overweight to Sector Weight...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) plunged Thursday after the release of its fourth-quarter results. The company reported a narrower-than-expected loss for Q4 and provided a corporate update. The Analyst Morgan Stanley analyst Matthew Harrison downgraded shares of Portola Pharma from...

SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals.  It found further reason to celebrate Monday with the conversion of a new Street advocate. The Rating Morgan Stanley...

"Age is just a number, not a state of mind or a reason for any type of particular behavior." -Cecelia Ahern Alzheimer's disease is the sixth leading cause of death in the U.S., although recent estimates indicate it may now be the third most common cause of death, behind heart disease...